Want to see KROS full AI Analyst Report?
KROS Stock Chart & Stats
$10.06
$0.28(2.78%)
At close: 4:00 PM EDT
$10.06
$0.28(2.78%)
Day’s Range― - ―
52-Week Range$9.69 - $22.55
Previous CloseN/A
Volume34.91K
Average Volume (3M)282.35K
Market Cap
$218.69M
Enterprise Value-$30.02
Total Cash (Recent Filing)$257.61M
Total Debt (Recent Filing)$15.72M
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Nov 11, 2026EPS Estimate
-0.94Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.70
Shares Outstanding19,827,188
10 Day Avg. Volume184,860
30 Day Avg. Volume282,353
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)2.50
Price to Sales (P/S)3.11
P/FCF Ratio7.15
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$18.80Price Target Upside86.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-5.44
Revenue Forecast (FY)$16.37M
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet And Low LeverageLow leverage and substantial assets provide financial flexibility for continued research and clinical development. This reduces near-term reliance on debt financing, although ongoing losses could gradually erode the company’s equity base.
Strategic Takeda Partnership Validates ElriterceptThe global Takeda agreement provides external validation, non-dilutive funding and a pathway toward additional milestones exceeding $1.1B plus royalties. Phase 3 initiation also advances the lead partnered asset toward potential commercialization.
Broad TGF-beta Pipeline Across High-need DiseasesA platform focused on TGF-beta signaling gives Keros several opportunities across diseases with significant unmet need. Diversification beyond one indication can improve long-term strategic value if clinical data support efficacy and safety.
Bears Say
Revenue And Earnings Lack DurabilityThe sharp reversal shows that reported profitability is heavily influenced by milestone-style or non-recurring revenue rather than established product sales. Until recurring commercial revenue emerges, earnings power will remain difficult to forecast.
Persistent Cash Burn Creates Funding RiskA clinical-stage model requires sustained investment before product commercialization, and recurring cash burn can shorten the funding runway. If milestone receipts or positive cash flow do not recur, future development may require additional capital.
CFO Transition Adds Execution RiskThe interim finance leadership arrangement appears managed, but a senior finance vacancy can create additional execution and reporting risk while the company searches for a permanent CFO. This matters as funding and clinical milestones remain critical.
Keros Therapeutics News
KROS FAQ
What was Keros Therapeutics, Inc.’s price range in the past 12 months?
Keros Therapeutics, Inc. lowest stock price was $9.69 and its highest was $22.55 in the past 12 months.
What is Keros Therapeutics, Inc.’s market cap?
Keros Therapeutics, Inc.’s market cap is $218.69M.
When is Keros Therapeutics, Inc.’s upcoming earnings report date?
Keros Therapeutics, Inc.’s upcoming earnings report date is Nov 11, 2026 which is in 78 days.
How were Keros Therapeutics, Inc.’s earnings last quarter?
Keros Therapeutics, Inc. released its earnings results on Aug 03, 2026. The company reported -$1.45 earnings per share for the quarter, missing the consensus estimate of -$1.34 by -$0.11.
Is Keros Therapeutics, Inc. overvalued?
According to Wall Street analysts Keros Therapeutics, Inc.’s price is currently Undervalued.
Does Keros Therapeutics, Inc. pay dividends?
Keros Therapeutics, Inc. does not currently pay dividends.
What is Keros Therapeutics, Inc.’s EPS estimate?
Keros Therapeutics, Inc.’s EPS estimate is -0.94.
How many shares outstanding does Keros Therapeutics, Inc. have?
Keros Therapeutics, Inc. has 19,827,188 shares outstanding.
What happened to Keros Therapeutics, Inc.’s price movement after its last earnings report?
Keros Therapeutics, Inc. reported an EPS of -$1.45 in its last earnings report, missing expectations of -$1.34. Following the earnings report the stock price went up 1.385%.
Which hedge fund is a major shareholder of Keros Therapeutics, Inc.?
Currently, no hedge funds are holding shares in KROS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Keros Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$18.80 (86.88% Upside)
$18.80 (86.88% Upside)
Blogger Sentiment
Bullish
KROS Sentiment 67%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $49.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 9.5%
Last 30 Days ▲ 9.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.39%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-62.02%
Trailing 12-Months
Company Description
Keros Therapeutics, Inc.
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.
KROS Stock 12 Month Forecast
Average Price Target
$18.80
▲(86.88% Upside)
Technical Analysis
Gyre Therapeutics
―
―
Palvella Therapeutics
―
Nurix Therapeutics
―
Bicara Therapeutics Inc.
―
Ownership Overview
5.19% Insiders
19.54% Mutual Funds
21.63% Other Institutional Investors
39.62% Public Companies and
Individual Investors